The double burden of tighter enforcement, slower implementation
India’s pharma MSMEs are facing a tough transition to revised GMP norms, hampered by slow implementation of the very schemes that…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Revised Schedule-M
The high cost of compromise: Why patient safety must come first
Dr Ranjit Barshikar, CEO – QbD International, United Nations Advisor cautions that India’s reputation as the ‘Pharmacy of the…
FOPE & PharmaState Academy advance MSME excellence with PULSE session 24 on contract management
Industry leaders underscore the vital role of contract management in ensuring compliance, sustainability, and global…
Session 21 of FOPE, PharmaState Academy’s PULSE Program, advances excellence in manufacture of APIs…
The keynote address was given by Namit Joshi, Chairman, Pharmexcil, followed by the expert educator session by Dr Jitender…
FOPE, PharmaState Academy’s 16th PULSE Session held on Oral Liquids manufacturing under Revised…
The session opened with a keynote address by Dr Viranchi Shah, followed by an education segment led by Abhijit S. Kulkarni, VP CQA…
What the new drug rules mean for quality control in Pharma: From lab to license
Dr Saurabh Arora, Managing Director, Auriga Research, explains how prioritising integrity, infrastructure, digital systems, and…
FOPE and PharmaState Academy conduct session on sterile drug manufacturing under Revised Schedule M
Session 18 of the PULSE initiative focuses on regulatory compliance, operational standards, and technical readiness in sterile…
FOPE & PharmaState Academy conducts session 17 on gap analysis and implementation plan for…
A structured and well-documented Gap Analysis is essential for identifying deficiencies, strengthening compliance, and ensuring…
Understanding opportunities and challenges for SMEs after breather on Schedule M deadline
Akshansh Chaudhary, Executive Director & Chief Technical Officer, Venus Remedies highlights the challenges SMEs face and how…
Pharma MSMEs ask for condition-free time frame of 2-3 years to implement revised Schedule M
In a letter to the Union Health Ministry, Small & Medium Pharma Manufacturers Association stated that pharma MSMEs are not…